Search
Quinidine
go.drugbank.com/drugs/DB00908Approved[A38016] It prolongs cellular action potential by blocking sodium and potassium currents. … A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug.
Metocurine iodide
go.drugbank.com/drugs/DB00416ApprovedWithdrawnMetocurine Iodide is no longer available on the US market. … Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation.
Trastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigationalIn November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda.[L49339] … Kanjinti (trastuzumab-anns)[L14135] and Hercessi[L52840] are other biosimilars approved by the FDA. In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved.
Donidalorsen
go.drugbank.com/drugs/DB18751ApprovedInvestigational[L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783] … Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of severe swelling induced by excessive production of bradykinin.
Synonyms: -(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL), DNA, D((2'-O-(2-METHOXYETHYL))M5RU-SP-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RA-SP-G-SP-T-SP-M5C-SP-T-SP-M5C-SP-T-SP-T-SP-G-SP-G-SP-M5C-SPRavulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigational[A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis. … [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.
Doxercalciferol
go.drugbank.com/drugs/DB06410ApprovedInvestigationalDoxercalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc. … Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin
Ranolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigational[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440]
Tapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigational[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMargetuximab
go.drugbank.com/drugs/DB14967ApprovedInvestigational[A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcγRIIIA/CD16A receptor, whereby low affinity … Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by _ERBB2_ overexpression, a higher grade, a more aggressive phenotype, and a worse prognosis compared to HER2-negative
Calcitriol
go.drugbank.com/drugs/DB00136ApprovedInvestigationalNutraceuticalIn addition to promoting fatty acid synthesis and inhibiting lipolysis, calcitriol has been demonstrated to increase energy efficiency by suppressing UCP2 expression, which is modulated by signaling pathways … Calcitriol plays a role in plasma calcium regulation in concert with parathyroid hormone (PTH) by enhancing absorption of dietary calcium and phosphate from the gastrointestinal tract, promoting renal
Products: RO-CAL 0.25mcg